Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

New Enhanze clinical trial posted today for “phase II trial tests whether subcutaneous atezolizumab can be effectively given AT HOME”

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Sponsor:
University of Southern California
Collaborators:
National Cancer Institute (NCI)
Genentech, Inc.
Information provided by (Responsible Party):
University of Southern California

“Brief Summary:
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.”

https://clinicaltrials.gov/ct2/show/NCT05340309?term=RhuPh20&draw=5&rank=56